# Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

> **NCT06791291** · PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 10 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Teplizumab

## Key facts

- **NCT ID:** NCT06791291
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2028-03-06
- **Final completion:** 2028-03-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06791291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06791291, "Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06791291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*